Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2019055657 - BAF COMPLEX MODULATING COMPOUNDS AND METHODS OF USING THE SAME

Publication Number WO/2019/055657
Publication Date 21.03.2019
International Application No. PCT/US2018/050888
International Filing Date 13.09.2018
IPC
C07D 273/02 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
273Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/-C07D271/183
02having two nitrogen atoms and only one oxygen atom
C07D 405/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
C07D 413/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14containing three or more hetero rings
CPC
C07D 273/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
273Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
02having two nitrogen atoms and only one oxygen atom
C07D 413/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
C07D 413/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14containing three or more hetero rings
Applicants
  • THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US]/[US]
Inventors
  • CHORY, Emma J.
  • CRABTREE, Gerald R.
  • DYKHUIZEN, Emily C.
Agents
  • FOULDS, Glenn J.
Priority Data
62/558,78414.09.2017US
62/697,03312.07.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BAF COMPLEX MODULATING COMPOUNDS AND METHODS OF USING THE SAME
(FR) COMPOSÉS DE MODULATION DE COMPLEXES BAF ET LEURS PROCÉDÉS D'UTILISATION
Abstract
(EN)
The invention provided here creates a new paradigm for the treatment of a variety of conditions where modulation of a BAF complex is desired. The disclosure that follows outlines a strategy for modulating a BAF complex in a cell, and provides effective compounds, pharmaceutical compositions, development strategies, and treatment protocols, and describes many of the ensuing benefits. A new family of BAF complex modulating compounds has been developed based on a new chemical scaffold including a 12-membered macrolactam core structures. Contacting target cells in vitro or in vivo with the compounds and compositions of this invention can selectively inhibit the activity of BAF complexes in such cells. Some of the BAF complex modulating compounds in this family are particularly effective agents for treating cancer in conjunction with a ATR inhibitor.
(FR)
L'objet de la présente invention est de fournir un nouveau paradigme pour le traitement de divers états pathologiques dans lesquels la modulation d'un complexe BAF est recherchée. L'invention se rapporte à une stratégie de modulation d'un complexe BAF dans une cellule, et concerne des composés efficaces, des compositions pharmaceutiques, des stratégies de développement et des protocoles de traitement, et décrit également plusieurs avantages qui en découlent. L'invention concerne une nouvelle famille de composés modulateurs du complexe BAF développée sur la base d'un nouvel échafaudage chimique comprenant des structures à noyau de macrolactame à 12 chaînons. La mise en contact de cellules cibles in vitro ou in vivo avec les composés et les compositions selon la présente invention peut inhiber de manière sélective l'activité de complexes BAF dans de telles cellules. Certains composés modulateurs du complexe BAF dans cette famille sont particulièrement efficaces pour le traitement du cancer conjointement avec un inhibiteur d'ATR.
Also published as
Latest bibliographic data on file with the International Bureau